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Multidrug-Resistant Tuberculosis
Lia D’Ambrosio, M.A., Rosella Centis, M.Sc., and Giovanni B. Migliori, M.D.
Fondazione Salvatore Maugeri Tradate, Italy
TO THE EDITOR
The study by Gler et al. (June 7 issue)1 provides a needed reminder regarding the 
development pipeline for drugs for tuberculosis and multidrug-resistant (MDR) 
tuberculosis.2 Delamanid with bedaquiline is increasing the potential for improving current 
regimens for tuberculosis. In their editorial in the same issue, Chaisson and Nuermberger3 
go one step further, posing the question of how these drugs should be used and highlighting 
the need for combination trials to maximize effectiveness and minimize negative drug 
interactions among new drugs for tuberculosis.
These issues are of key importance. Knowing the complexity of tuberculosis control and the 
difficulty of limiting dangerous misuse of drugs in the community, it is imperative that those 
of us who are involved in public health, health policy, and the treatment of patients with 
tuberculosis face the issue of the rational use of drugs for tuberculosis. The mistakes we 
committed with rifampin and the fluoroquinolones4,5 are readily evident. The reality is that 
single new drugs will inevitably be used in the community regardless of who develops them 
and the regulatory indications for them. The only solution is to anticipate the challenges of 
the misuse of new drugs well before any combination regimen is conceived and developed.
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